Weyco Group reported a 5% increase in net sales to $77 million and net earnings of $11.5 million for Q3 2026, nearly doubling from $6.6 million in Q3 2025. Growth was driven by strong sales in North America, especially from the Florsheim brand, and improved gross margins aided by tariff refunds. The company declared a special cash dividend of $2.00 per share alongside the regular quarterly dividend. Weyco remains focused on sustaining sales growth and profitability amid evolving U.S. trade policies.
Weyco's third quarter 2026 net sales rose 5% to $77 million, with net earnings nearly doubling to $11.5 million. For readers following the Consumer Cyclical sector, here is Pluang's market snapshot as of Nov 04, 2026 03:41 WIB: out of 134 priced US stocks, 42 advanced and 91 declined. Notable movers include BALL at USD 63.90 with a 1-day change of -6.13% and 100% buy order activity, APTV at USD 41.56 down 6.04% with 58% buy orders, and NEGG at USD 9.20 down 5.25% with 42% buy orders.
Nova Klúbburinn hf. has completed a share buyback program, acquiring 122,699,386 shares at an average price of ISK 3.26 per share. The buyback was part of an inverse offer process with valid bids for 159,526,476 shares. The company accepted bids up t...
AMC Entertainment will release its Q3 2026 earnings on Nov. 4, following a year-over-year increase in North American box-office receipts to about $3.1 billion from $2.5 billion in Q3 2025. The quarter featured major film releases like Spider-Man: Bra...
Pomerantz LLP is investigating Erasca, Inc. following the termination of its COO, Nicholas Chetwyn, which led to a nearly 10% drop in the company's stock price. The investigation focuses on whether Erasca and its executives engaged in securities frau...
Pomerantz LLP is investigating claims against Yiren Digital Ltd. for possible securities fraud following the company's disclosure of a 34% revenue decline and a significant net loss in Q4 2025. The company also reported increased delinquency rates an...
Pomerantz LLP is investigating Syndax Pharmaceuticals following the company's announcement that its Phase 2 trial for axatilimab in idiopathic pulmonary fibrosis failed to meet its primary endpoint. This news caused Syndax's stock to drop by 2.59% on...
